Zinforo®: Mode of Action (MOA)

Zinforo®: Potent bactericidal activity against resistant isolates with high-binding affinity to mutated beta-lactam-binding proteins1-6

Zinforo® binds with high affinity to MRSA PBP2a and MSSA PBPs:1-3,6

How does Zinforo® exert bacterial activity?

Zinforo® exerts potent bactericidal activity in cSSTI against resistant isolates with high-binding affinity to mutated beta-lactam-binding proteins7-12

It enforces bactericidal activity in CAP against resistant isolates with high-binding affinity in S. pneumoniae.7-9

cSSTI: complicated skin and soft tissue infections; CAP: community acquired pneumonia; MRSA: Methicillin-resistant Staphylococcus aureus; PBP2a: Penicillin-binding protein 2a; PBPs: penicillin-binding proteins.

References:
1. Garrison MW, Kawamura NM, Wen MM. Expert Rev Anti Infect Ther 2012; 10:1087–103.
2. Drusano GL. J Antimicrob Chemother 2011; 66(Suppl. 3):iii61–iii67.
3. Casapao AM, Davis SL, Barr VO, et al. Antimicrob Agents Chemother 2014; 58:2541–6.
4. Ishikawa T, Matsunaga N, Tawada H, et al. Bioorg Med Chem 2003;11:2427–37.
5. Laudano JB. J Antimicrob Chemother 2011; 66(Suppl. 3):iii11–iii18.
6. Moisan H, Pruneau M, Malouin F. J Antimicrob Chemother 2010;65:713–16.
7. Laudano JB. J Antimicrob Chemother 2011; 66(Suppl. 3):iii11–iii18;
8. Garrison MW, Kawamura NM, Wen MM. Expert Rev Anti Infect Ther 2012; 10:1087–103;
9. Drusano GL. J Antimicrob Chemother 2011; 66(Suppl. 3):iii61–7;
10. Casapao AM, Davis SL, Barr VO, et al. Antimicrob Agents Chemother 2014; 58:2541–6;
11. Ishikawa T, Matsunaga N, Tawada H, et al. Bioorg Med Chem 2003;11:2427–37;
12. Moisan H, Pruneau M, Malouin F. J Antimicrob Chemother 2010;65:713–16.

PP-ZFO-IND-0279.  09 December 2021
Please click on Prescribing Information link to view safety and adverse events information of Zinforo.
For the use only of registered medical practitioner, or a hospital or a laboratory.